Tools for Practice Outils pour la pratique


#425 Don’t Lose Sleep Over When to Take Blood Pressure Medications


CLINICAL QUESTION
QUESTION CLINIQUE
In adults with hypertension, does taking once-daily antihypertensive drugs at bedtime, rather than in the morning, reduce cardiovascular events or death?


BOTTOM LINE
RÉSULTAT FINAL
In patients with hypertension, taking antihypertensive drugs in the evening does not reduce the risk of cardiovascular events or death compared with morning administration. Consider a default of morning dosing for once-daily antihypertensive medications; timing can then be tailored to patient preferences and convenience to support adherence.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • 5 systematic reviews of randomized controlled trials (RCTs) in the past 2 years compared cardiovascular events when taking ≥1 antihypertensive drugs at bedtime/evening versus taking them all in the morning.1–5
  • Focusing on systematic reviews comparing timing only (excluding RCTs with different drugs in the intervention and comparator groups):1–3
    • 5 RCTs with 46,606 patients (mean age 63 years, 45% women).
    • Over a median 5.2 years of follow-up, no statistically significant difference in cardiovascular events1,2 or deaths.1–3
  • Inconsistent results between trials driven by 2 RCTs by the same group (Hygia and MAPEC) at risk of bias.1,6
  • Focusing on 3 RCTs at low risk of bias (Canadian BedMed7 and BedMed-Frail8, and the UK TIME9):
    • No difference in cardiovascular events, death, cognition, fractures, or glaucoma.1
    • More patients randomized to morning administration took their medications at the allocated time.7,9

CONTEXT
CONTEXTE
  • Rationale for bedtime dosing based on observational studies suggesting that nighttime blood pressure better predicts cardiovascular events than daytime or in-office measurement, and that absence of the natural decline in blood pressure during sleep (“non-dipping”) is associated with increased cardiovascular risk.6,10
  • Taking antihypertensive drugs in the evening lowered 24-hour ambulatory blood pressure by ~1-2 mmHg compared with morning administration, but not statistically different after excluding trials by the Hygia/MAPEC investigators.11
  • A previous Tools for Practice based on the MAPEC trial suggested taking antihypertensive drugs at night might reduce cardiovascular events, but cautioned about several important trial limitations.10
  • Guidelines emphasize the importance of antihypertensive drug adherence and recommend they be taken at the most convenient time of day for an individual patient, noting the evidence showing administration time does not alter cardiovascular risk reduction.12


Latest Tools for Practice
Derniers outils pour la pratique

#425 Don’t Lose Sleep Over When to Take Blood Pressure Medications

In adults with hypertension, does taking once-daily antihypertensive drugs at bedtime, rather than in the morning, reduce cardiovascular events or death?
Read Lire 0.25 credits available Crédits disponibles

#424 Shoulder the Evidence: Steroid injections for shoulder pain

What are the effects of steroid injections for rotator cuff related pain and is ultrasound guidance needed?
Read Lire 0.25 credits available Crédits disponibles

#423 Estrogen – an answer to a burning question?

Does estrogen reduce urinary tract infections (UTIs) in post-menopausal women?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Ricky Turgeon BSc(Pharm) ACPR PharmD
  • Scott Garrison MD PhD CCFP

1. Turgeon RD, MacDonald BJ, Garrison SR. Can J Cardiol. 2025;41: 2575-83.

2. Hiruma Y, Shimoda TM, Watanabe A, et al. J Cardiol. 2026;87: 565-7.

3. Rakab MS, Elsalakawi BH, Shubietah A, et al. High Blood Press Cardiovasc Prev. 2025;33: 41-55.

4. Wang T, Lai S, Wang D, Wang X. Front Pharmacol. 2026;17: 1758890.

5. Parreira VV, Cheidde L, Silva AD, et al. J Hum Hypertens. 2026;40: 515-22.

6. Turgeon RD, Althouse AD, Cohen JB, et al. Hypertension. 2021;78: 871-8.

7. Garrison SR, Bakal JA, Kolber MR, et al. JAMA. 2025;333: 2061-72.

8. Garrison SR, Youngson ERE, Perry DA, et al. JAMA Netw Open. 2025;8: e2513812.

9. Mackenzie IS, Rogers A, Poulter NR, et al. Lancet. 2022;400: 1417-25.

10. Turgeon R, Allan GM. Can Fam Physician. 2012;58: 965.

11. Wu C, Zhao P, Xu P, et al. Cochrane Database Syst Rev. 2024;2: CD004184.

12. McEvoy JW, McCarthy CP, Bruno RM, et al. Eur Heart J. 2024;45: 3912-4018.

Dr. Garrison held grants from the Canadian Institutes of Health Research and Alberta Innovates (Government of Alberta) for the BedMed and BedMed-Frail RCTs. Dr. Turgeon has no conflicts to disclose.